Chinese Expert Consensus on Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations (2023 Edition).
10.3779/j.issn.1009-3419.2023.106.10
- Collective Name:Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Committee
- Publication Type:Journal Article
- Keywords:
Consensus;
Epidermal growth factor receptor exon 20 insertion mutations;
Lung neoplasms
- MeSH:
Humans;
Carcinoma, Non-Small-Cell Lung/therapy*;
Consensus;
ErbB Receptors/genetics*;
Exons;
Lung Neoplasms/therapy*;
Mutagenesis, Insertional
- From:
Chinese Journal of Lung Cancer
2023;26(5):325-337
- CountryChina
- Language:Chinese
-
Abstract:
With the development of precision diagnosis and treatment for non-small cell lung cancer (NSCLC), the epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations, as a rare subset of EGFR mutaions, have gradually attracted attention recently. The heterogeneity of EGFR ex20ins mutations is very high, different variants have different clinical benefits, and the prognosis is extremely poor. The available traditional treatment outcomes are poor in patients with EGFR ex20ins positive NSCLC and polymerase chain reaction (PCR) tests would miss aprocimately 50% of the variants. Therefore, high attention should be paid to EGFR ex20ins positive NSCLC during the clinical practice. The expert panel has formed a consensus on the standardized clinical diagnosis and treatment of EGFR ex20ins mutation NSCLC through reference to literature and clinical data, and combined with the experts' own clinical experience, the consensus recommendations including clinicopathologic characteristics, therapies, testing methods and recent relevant clinical trials for NSCLC patients with EGFR ex20ins mutation, in order to provide medication reference for clinical physicians at all levels.
